|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raoul JL, Kudo M, Finn RS, Edeline J, Reig
M and Galle PR: Systemic therapy for intermediate and advanced
hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev.
68:16–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El Dika I and Abou-Alfa GK: The role (if
any) of chemotherapy in hepatocellular carcinoma. Lancet
Gastroenterol Hepatol. 2:387–389. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C,
Lv Y, Zhou Z and Liu Z: Hepatocellular carcinoma in a large medical
center of China over a 10-year period: Evolving therapeutic option
and improving survival. Oncotarget. 6:4440–4450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan LH, Zhao C and Ma YL: Is Y90
radioembolization superior or comparable to transarterial
chemoembolization for treating hepatocellular carcinoma?
Gastroenterology. 152:1627–1628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peck-Radosavljevic M: Drug therapy for
advanced-stage liver cancer. Liver Cancer. 3:125–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Govaere O, Wouters J, Petz M, Vandewynckel
YP, Van den Eynde K, Van den Broeck A, Verhulst S, Dollé L,
Gremeaux L, Ceulemans A, et al: Laminin-332 sustains
chemoresistance and quiescence as part of the human hepatic cancer
stem cell niche. J Hepatol. 64:609–617. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Ye Y, Feng B and Qi Y: Long
noncoding RNA lncARSR promotes doxorubicin resistance in
hepatocellular carcinoma via modulating PTEN-PI3K/Akt pathway. J
Cell Biochem. 118:4498–4507. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Noiva R: Protein disulfide isomerase: The
multifunctional redox chaperone of the endoplasmic reticulum. Semin
Cell Dev Biol. 10:481–493. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia W, Zhuang J, Wang G, Ni J, Wang J and
Ye Y: P4HB promotes HCC tumorigenesis through downregulation of
GRP78 and subsequent upregulation of epithelial-to-mesenchymal
transition. Oncotarget. 8:8512–8521. 2017.PubMed/NCBI
|
|
12
|
Sun S, Wong TS, Zhang XQ, Pu JK, Lee NP,
Day PJ, Ng GK, Lui WM and Leung GK: Protein alterations associated
with temozolomide resistance in subclones of human glioblastoma
cell lines. J Neurooncol. 107:89–100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee D, Sun S, Ho AS, Kiang KM, Zhang XQ,
Xu FF and Leung GK: Hyperoxia resensitizes chemoresistant
glioblastoma cells to temozolomide through unfolded protein
response. Anticancer Res. 34:2957–2966. 2014.PubMed/NCBI
|
|
14
|
Wang SM, Lin LZ, Zhou DH, Zhou JX and
Xiong SQ: Expression of prolyl 4-hydroxylase beta-polypeptide in
non-small cell lung cancer treated with Chinese medicines. Chin J
Integr Med. 21:689–696. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wilson C, Nicholes K, Bustos D, Lin E,
Song Q, Stephan JP, Kirkpatrick DS and Settleman J: Overcoming
EMT-associated resistance to anti-cancer drugs via Src/FAK pathway
inhibition. Oncotarget. 5:7328–7341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sánchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q,
Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated
adriamycin-induced epithelial-mesenchymal transition relates to
multidrug resistance and invasive potential in breast cancer cells.
Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palma Cde S, Grassi ML, Thomé CH, Ferreira
GA, Albuquerque D, Pinto MT, Ferreira Melo FU, Kashima S, Covas DT,
Pitteri SJ and Faça VM: Proteomic analysis of epithelial to
mesenchymal transition (EMT) reveals cross-talk between SNAIL and
HDAC1 proteins in breast cancer cells. Mol Cell Proteomics.
15:906–917. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The Role of Snail in EMT and tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Angers S and Moon RT: Proximal events in
Wnt signal transduction. Nat Rev Mol Cell Biol. 10:468–477. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nowicki A, Sporny S and Duda-Szymańska J:
β-catenin as a prognostic factor for prostate cancer (PCa). Cent
European J Urol. 65:119–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ghahhari NM and Babashah S: Interplay
between microRNAs and WNT/β-catenin signalling pathway regulates
epithelial-mesenchymal transition in cancer. Eur J Cancer.
51:1638–1649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen W, Yang J, Zhang Y, Cai H, Chen X and
Sun D: Regorafenib reverses HGF-induced sorafenib resistance by
inhibiting epithelial-mesenchymal transition in hepatocellular
carcinoma. FEBS Open Bio. 9:335–347. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roy S, Kar M, Roy S, Saha A, Padhi S and
Banerjee B: Role of β-catenin in cisplatin resistance, relapse and
prognosis of head and neck squamous cell carcinoma. Cell Oncol
(Dordr). 41:185–200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang D, Qian G, Wang J, Wang T, Zhang L,
Yang P and Lin F: Visfatin is involved in the cisplatin resistance
of osteosarcoma cells via upregulation of Snail and Zeb1. Cancer
Biol Ther. 20:999–1006. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Patel N, Garikapati KR, Makani VKK, Nair
AD, Vangara N, Bhadra U and Pal Bhadra M: Regulating BMI1
expression via miRNAs promote mesenchymal to epithelial transition
(MET) and sensitizes breast cancer cell to chemotherapeutic drug.
PLoS One. 13:e01902452018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Batlle E, Sancho E, Francí C, Domínguez D,
Monfar M, Baulida J and García De Herreros A: The transcription
factor snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peinado H, Ballestar E, Esteller M and
Cano A: Snail mediates E-cadherin repression by the recruitment of
the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell
Biol. 24:306–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pastushenko I, Brisebarre A, Sifrim A,
Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D,
Moers V, Lemaire S, et al: Identification of the tumour transition
states occurring during EMT. Nature. 556:463–468. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang G, Fang X, Yang Y and Song Y:
Silencing of CEMIP suppresses Wnt/β-catenin/Snail signaling
transduction and inhibits EMT program of colorectal cancer cells.
Acta Histochem. 120:56–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
